Galecto, Inc. (GLTO)

0.7006 +0.0196 (+2.88%) At close: 04:00PM EDT

Galecto, Inc.

Ole Maaloes Vej 3
Copenhagen N
Copenhagen 2200
Denmark
45 70 70 52 10
https://galecto.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 13

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Hans T. Schambye M.D., Ph.D.	Co-Founder, President, CEO & Director	700.13k	N/A	1966
Mr. Jonathan P. Freve CPA, CPA	Chief Financial Officer	604.93k	N/A	1978
Mr. Ulf J. Nilsson	Co-Founder	N/A	N/A	N/A
Dr. Hakon Leffler	Co-Founder	N/A	N/A	N/A
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Garrett Winslow Esq.	Senior VP, General Counsel & Corporate Secretary	N/A	N/A	1979

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Corporate Governance

Galecto, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.